All In Biotech

Drug Trial Radar · NCT03571230

Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.

10-Day Antimicrobial Susceptibility Testing Guided Triple Therapy Versus 14-Day Empirical Tailored Therapy for the First-line Treatment of Helicobacter Pylori Infection-A Randomized Controlled Trail

Last checked: Nov 19, 2026Latest source record: Jun 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 1, 2018

Primary completion

Dec 30, 2019

Study completion Jan 30, 2020

Sponsor

Lead sponsor
Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy of 10-day antimicrobial susceptibility test guided triple therapy for the first-line treatment of Helicobacter pylori infection, then comparing it with 14-day empirical tailored therapy to tell which one has a better performance in both efficacy and safety.

Conditions

  • Helicobacter Pylori Infection
  • Antimicrobial Susceptibility Testing

Interventions

  • two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)Drug

    Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.

  • two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)Drug

    Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.

  • one proton pump inhibitor(PPI)Drug

    All the patients need this drug.

  • Colloidal Bismuth PectinDrug

    All the patients treated with 14-day bismuth-based quadruple therapy need this drug.

  • two antibiotics for failed eradication(tetracyclin,furazolidone)Drug

    If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rates in 2 groupsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiuli Zuo

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.